Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (93)
February 18, 2008
-
Maurer's Healthcare Insight (92)
January 21, 2008
-
Maurer's Healthcare Insight (91)
December 24, 2007
-
Maurer's Healthcare Insight (90)
November 5, 2007
-
Maurer's Healthcare Insight (89)
October 8, 2007
-
Maurer's Healthcare Insight (88)
August 6, 2007
-
Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
-
Maurer's Healthcare Insight (86)
May 28, 2007
-
Maurer's Healthcare Insight (85)
April 16, 2007
-
Maurer's Healthcare Insight (84)
March 26, 2007
-
Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
-
Maurer's Healthcare Insight (83)
February 19, 2007
-
2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
-
Maurer's Healthcare Insight (82)/Questions from the Floor P. Reed Maurer
December 18, 2006
-
Maurer's Healthcare Insight (81)
November 20, 2006
-
Maurer's Healthcare Insight (80)
October 23, 2006
-
Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
-
Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
-
Maurer's Healthcare Insight (77)
July 24, 2006
-
Maurer's Healthcare Insight (76)
June 26, 2006
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…